Cytomegalovirus in the Pediatric Transplant Recipient: Where Are We Now?
作者信息
Michaels Marian G, Humar Atul
机构信息
1 Division of Infectious Diseases, Pediatric Transplant Infectious Diseases Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA. 2 Multi-Organ Transplant Program University Health Network Toronto General Hospital, Toronto, ON, Canada.
出版信息
Transplantation. 2017 Apr;101(4):686-687. doi: 10.1097/TP.0000000000001627.
Abstract
摘要
相似文献
1
Cytomegalovirus in the Pediatric Transplant Recipient: Where Are We Now?儿科移植受者中的巨细胞病毒：我们目前的状况如何？
Transplantation. 2017 Apr;101(4):686-687. doi: 10.1097/TP.0000000000001627.
2
Prevention and Treatment of Cytomegalovirus Infections in Solid Organ Transplant Recipients.实体器官移植受者巨细胞病毒感染的预防和治疗。
Infect Dis Clin North Am. 2018 Sep;32(3):581-597. doi: 10.1016/j.idc.2018.04.008.
3
Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.抗病毒预防治疗停止后儿科肾移植受者巨细胞病毒血症的发生率。
Transplantation. 2018 Aug;102(8):1391-1396. doi: 10.1097/TP.0000000000002115.
4
Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.缬更昔洛韦用于小儿实体器官移植受者巨细胞病毒预防的剂量：一项前瞻性药代动力学研究。
Pediatr Infect Dis J. 2017 Aug;36(8):745-750. doi: 10.1097/INF.0000000000001595.
5
A risk-stratified approach to cytomegalovirus prevention in pediatric solid organ transplant recipients.小儿实体器官移植受者巨细胞病毒预防的风险分层方法。
Pediatr Transplant. 2016 Nov;20(7):970-980. doi: 10.1111/petr.12786. Epub 2016 Aug 26.
6
Immune-based guidance of foscarnet treatment duration in a transplant recipient with ganciclovir-resistant cytomegalovirus infection.基于免疫的膦甲酸钠治疗持续时间指导：用于一名患有耐更昔洛韦巨细胞病毒感染的移植受者
J Clin Virol. 2016 Sep;82:5-8. doi: 10.1016/j.jcv.2016.06.013. Epub 2016 Jun 22.
7
Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients.供体和受体巨细胞病毒血清学对心脏移植受者长期生存的影响。
Transpl Infect Dis. 2019 Feb;21(1):e13015. doi: 10.1111/tid.13015. Epub 2018 Nov 19.
8
Would Kinetic Analyses of Plasma Cytomegalovirus DNA Load Help to Reach Consensus Criteria for Triggering the Initiation of Preemptive Antiviral Therapy in Transplant Recipients?血浆巨细胞病毒DNA载量的动力学分析是否有助于达成移植受者启动抢先抗病毒治疗的共识标准？
Clin Infect Dis. 2016 Dec 1;63(11):1533-1535. doi: 10.1093/cid/ciw608. Epub 2016 Aug 30.
9
Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status.根据供者 CMV 血清学状态，造血干细胞移植受者巨细胞病毒（CMV）再激活后的抗病毒治疗反应。
Clin Microbiol Infect. 2016 Mar;22(3):289.e1-7. doi: 10.1016/j.cmi.2015.11.006. Epub 2015 Nov 25.
10
Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.抗病毒预防时代肾移植受者的巨细胞病毒血症与死亡率。西澳大利亚经验教训。
BMC Infect Dis. 2017 Jul 17;17(1):501. doi: 10.1186/s12879-017-2599-y.
本文引用的文献
1
Effectiveness of Preemptive Therapy for Cytomegalovirus Disease in Pediatric Liver Transplantation.抢先治疗对小儿肝移植中巨细胞病毒疾病的有效性
Transplantation. 2017 Apr;101(4):804-810. doi: 10.1097/TP.0000000000001531.
2
Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis.肝移植后巨细胞病毒病的通用预防或先发制人的策略：系统评价和荟萃分析。
Am J Transplant. 2015 Feb;15(2):472-81. doi: 10.1111/ajt.13044. Epub 2014 Dec 17.
3
Cytomegalovirus infection in liver transplant recipients: updates on clinical management.肝移植受者的巨细胞病毒感染：临床管理的最新进展
World J Gastroenterol. 2014 Aug 21;20(31):10658-67. doi: 10.3748/wjg.v20.i31.10658.
4
Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation.更新的实体器官移植中巨细胞病毒管理的国际共识指南。
Transplantation. 2013 Aug 27;96(4):333-60. doi: 10.1097/TP.0b013e31829df29d.
5
Cytomegalovirus in solid organ transplantation.实体器官移植中的巨细胞病毒
Am J Transplant. 2013 Mar;13 Suppl 4:93-106. doi: 10.1111/ajt.12103.
6
Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study.D+/R- 肾移植受者延长缬更昔洛韦预防与长期减少巨细胞病毒病相关：IMPACT 研究的两年结果。
Transplantation. 2010 Dec 27;90(12):1427-31. doi: 10.1097/tp.0b013e3181ff1493.
7
OKT3 and viral disease in pediatric liver transplant recipients.OKT3与小儿肝移植受者的病毒疾病
Clin Transplant. 1991 Aug;5(4):294-300.
8
Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation.预防后进行抢先治疗与抢先治疗对肝移植儿科患者预防人巨细胞病毒病的比较
Transplantation. 2008 Jul 15;86(1):163-6. doi: 10.1097/TP.0b013e31817889e4.
9
Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children.静脉注射更昔洛韦后口服阿昔洛韦与单纯静脉注射更昔洛韦预防儿童肝移植后巨细胞病毒和EB病毒疾病的比较。
Clin Infect Dis. 1997 Dec;25(6):1344-9. doi: 10.1086/516139.
10
Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].口服更昔洛韦预防肝移植受者巨细胞病毒病疗效和安全性的随机试验。口服更昔洛韦国际移植研究组[校正后]
Lancet. 1997 Dec 13;350(9093):1729-33. doi: 10.1016/s0140-6736(97)05535-9.
Zotero 插件